-
甲状腺相关性眼病(thyroid associated ophthalmopathy,TAO)又称Graves眼病(Graves' ophthalmopathy, GO),属于浸润性突眼,是一种器官特异性自身免疫性疾病,其发病率约为42.2/100万,其中有20.1%的患者同时伴发甲状腺功能亢进症,发病高峰年龄为40~60岁,女性发病率明显高于男性,男女比例为1∶3.9,患者长期处于因眼球突出所致容貌改变和因复视造成的视力受损的痛苦中,严重影响其生活质量[1-3]。笔者通过分析2例患者99Tcm-DTPA SPECT/CT眼眶显像的不同结果探讨其在TAO活动期评估中的应用价值。
99Tcm-DTPA SPECT/CT在二例甲状腺相关性眼病患者活动期评估中的应用及文献复习
Application of 99Tcm-DTPA SPECT/CT in the activity assessment in two patients with thyroid associated ophthalmopathy and literature review
-
摘要: 笔者通过分析2例患者99Tcm-二亚乙基三胺五乙酸(DTPA) SPECT/CT眼眶显像的不同结果并结合文献复习,简述该影像学方法在甲状腺相关性眼病(TAO)活动期评估中的应用价值。目前临床常用的TAO活动期评估方法主要是通过患者的症状做出临床活动性评分(CAS),但轻、中度患者临床表现部分有重叠,单纯使用CAS评分不易鉴别,且该诊断具有一定主观性。通过病例分析,结果显示,99Tcm-DTPA SPECT/CT眼眶显像较CAS对非活动性TAO有着更高的阴性预测值,这说明该显像也能成为TAO评估的一种选择。Abstract: This paper briefly described the application value of this imaging method in the evaluation of active thyroid-related ophthalmopathy (TAO) by analyzing the different results of 99Tcm-diethylene triaminepentaacetic acid (DTPA) SPECT/CT orbital imaging in 2 patients and combined with literature review. At present, the commonly used clinical assessment of TAO active phase is mainly based on the clinical activity score (CAS) of the patient's symptoms, but the clinical manifestations of mild and moderate patients partially overlap, and it is not easy to identify using the CAS score alone, and the diagnosis is subject to a certain degree. The results of this study show that 99Tcm-DTPA SPECT/CT orbital imaging has a higher negative predictive value for inactive TAO than CAS, indicating that this imaging can also be an option for TAO assessment.
-
Key words:
-
图 1 甲状腺相关性眼病患者(男性,50岁)眼眶的99Tcm-DTPA SPECT/CT显像图 双侧下及内直肌肌腹明显增粗,显像剂摄取明显增强,符合甲状腺相关性眼病炎症活动期改变。A、B、C分别为眼眶冠状面、矢状面、横断面,每排从左至右依次为CT、SPECT及SPECT/CT融合图。DTPA:二亚乙基三胺五乙酸;SPECT:单光子发射计算机断层成像术;CT:计算机体层摄影术
Figure 1. 99Tcm-DTPA SPECT/CT orbital images in patient with thyroid associated ophthalmopathy(male, 50 years old)
图 2 甲状腺相关性眼病患者(男性,49岁)眼眶
的99Tcm-DTPA SPECT/CT显像图 右侧上直肌及外直肌增粗,显像剂摄取未见明显增强,考虑甲状腺相关性眼病非活动期改变。A、B、C分别为眼眶冠状面、矢状面、横断面,每排从左至右依次为CT、SPECT及SPECT/CT融合图。DTPA:二亚乙基三胺五乙酸;SPECT:单光子发射计算机断层成像术;CT:计算机体层摄影术 Figure 2. 99Tcm-DTPA SPECT/CT orbital images in patient with thyroid associated ophthalmopathy(male, 49 years old)
-
[1] Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9−26. DOI: 10.1159/000443828. [2] Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med, 2020, 382(4): 341−352. DOI: 10.1056/NEJMoa1910434. [3] Smith TJ, Hegedus L. Graves' disease[J]. N Engl J Med, 2016, 375(16): 1552−1565. DOI: 10.1056/NEJMra1510030. [4] 蒋承志, 李新辉, 邓豪余, 等. 99mTc-DTPA眼眶SPECT/CT显像非靶区及阈值的选择在甲状腺相关性眼病中的应用[J]. 中南大学学报: 医学版, 2018, 43(8): 869−874. DOI: 10.11817/j.issn.1672-7347.2018.08.008.
Jiang CZ, Li XH, Deng HY, et al. Nontarget area and threshold selection in 99mTc-DTPA orbital SPECT/CT imaging in thyroid associated ophthalmopathy[J]. J Cent South Univ: Med Sci, 2018, 43(8): 869−874. DOI: 10.11817/j.issn.1672-7347.2018.08.008.[5] 刘丹, 许雪亮, 文丹, 等. 99mTc-DTPA眼眶SPECT/CT对甲状腺相关性眼病炎性活动的评价[J]. 中南大学学报: 医学版, 2018, 43(4): 457−460. DOI: 10.11817/j.issn.1672-7347.2018.04.020.
Liu D, Xu XL, Wen D, et al. Evaluation of inflammatory activity in thyroid associated ophthalmopathy by SPECT/CT with 99mTc-DTPA[J]. J Cent South Univ (Med Sci), 2018, 43(4): 457−460. DOI: 10.11817/j.issn.1672-7347.2018.04.020.[6] Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO[J]. Eur J Endocrinol, 2008, 158(3): 273−285. DOI: 10.1530/EJE-07-0666. [7] Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008, 18(3): 333−346. DOI: 10.1089/thy.2007.0315. [8] Galuska L, Barna SK, Varga J, et al. The role of 99mTc-DTPA retrobulbar SPECT in staging and follow-up of Graves' orbitopathy[J]. Nucl Med Rev Cent East Eur, 2018, 21(1): 54−58. DOI: 10.5603/NMR.a2018.0005. [9] Szumowski P, Abdelrazek S, Żukowski Ł, et al. Efficacy of 99mTc-DTPA SPECT/CT in diagnosing Orbitopathy in graves' disease[J/OL]. BMC Endocr Disord, 2019, 19(1): 10[2021-02-08]. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-019-0340-0. DOI: 10.1186/s12902-019-0340-0. [10] Galuska L, Leovey A, Szucs-Farkas Z, et al. SPECT using 99mTc-DTPA for the assessment of disease activity in Graves' ophthalmopathy: a comparison with the results from MRI[J]. Nucl Med Commun, 2002, 23(12): 1211−1216. DOI: 10.1097/00006231-200212000-00010.